---
id: barabasi-network-medicine
slug: barabasi-network-medicine
entity_type: research
status: published
data_completeness: exceptional
last_researched: 2025-12-29
research_category: collaboration
researcher: AI Assistant
version: 4.2
name: Barabási–Gladyshev–Loscalzo Network Medicine for Hallmarks of Aging
description: "SHARP (Systematic Hallmark-based Aging Repurposing Pipeline): Network medicine framework integrating 2,358 longevity-associated genes into human interactome (18,223 proteins, 524,156 interactions) to systematically analyze 6,442 drugs across 11 hallmarks of aging. Results: 4,809 drugs show network proximity to hallmarks (370 meet stringent z<-1.96 threshold for targeted repurposing), ~3,000 drugs per hallmark have pAGE transcriptional data, 14 pro-longevity and 14 age-accelerating drugs identified. Validation: 82.4% accuracy on clinical trials, 90.9% on mouse ITP studies. Case study: Oxymetazoline demonstrates consistent positive pAGE (1.0→0.46) across 5 network levels for altered intercellular communication."
mission: Network medicine approach for drug repurposing targeting hallmarks of aging using SHARP pipeline
entity_data:
  name: Barabási–Gladyshev–Loscalzo Network Medicine
  status: published
  objectives:
  - Identify drug repurposing candidates targeting hallmarks of aging
  - Develop network medicine framework for systematic drug discovery
  - Integrate interactome proximity analysis with transcriptional reversal scoring
  - Provide interpretable, mechanism-based approach to drug nomination
  - Validate predictions against clinical trial and mouse lifespan data
  start_date: 2024-01-01
  description: "SHARP pipeline: Research collaboration analyzing 6,442 drugs across 11 hallmarks of aging. Identified 4,809 drugs with network proximity (370 meeting stringent significance threshold for targeted repurposing). ~3,000 drugs per hallmark validated with pAGE transcriptional reversal scoring. Achieved 82.4% clinical trial accuracy and 90.9% mouse lifespan accuracy."
  publication_date: 2025-09-03
  supplementary_data:
  data_availability: Code and data to reproduce all results and figures available in GitHub repository
  github_repository: "https://github.com/BnayaGross/Longevity-module"
  supplementary_tables:
  - "Table S5: Multi-hallmark drug profiles"
  - "Table S6: Complete drug profiles across all hallmarks"
  competing_interests:
  no_conflicts:
  - Bnaya Gross
  - Joseph Ehlert
  - Vadim N. Gladyshev
  declared_conflicts:
  -
  company: Scipher Medicine, Inc.
  persons:
  - Albert-László Barabási
  - Joseph Loscalzo
  relationship: Founders
  company_focus: Network medicine for biomarker development and personalized drug selection
  author_contributions:
  methodology:
  - Bnaya Gross
  supervision:
  - Vadim N. Gladyshev
  - Joseph Loscalzo
  - Albert-László Barabási
  investigation:
  - Bnaya Gross
  visualization:
  - Bnaya Gross
  conceptualization:
  - Bnaya Gross
  - Albert-László Barabási
  writing_original_draft:
  - Bnaya Gross
  - Albert-László Barabási
  writing_review_editing:
  - Bnaya Gross
  - Joseph Ehlert
  - Vadim N. Gladyshev
  - Joseph Loscalzo
  - Albert-László Barabási
  collaboration_period:
  start: 2024
  publication_date: 2025-09-03
taxonomy:
  geography: USA
  ai_technology:
  - Graph Neural Networks
  - Predictive ML/DL
  primary_focus:
  - AI-Driven Drug Discovery
  aging_approach:
  - Target Discovery
  target_biology:
  - General Aging/Longevity
  development_stage: Research / Preclinical
  organization_type: research
  organization_subtype: collaboration
  therapeutic_modality: []
organizations:
  -
    name: Network Science Institute, Northeastern University
    role: primary
    org_type: research_center
    website: "https://www.networkscienceinstitute.org/"
    status: operational
    role_description: Primary development institution
    contribution_description: Network Science Institute hosts Barabási Lab which developed SHARP pipeline and led computational framework implementation
  -
    name: Harvard Medical School
    role: primary
    org_type: institution
    website: "https://hms.harvard.edu/"
    status: operational
    role_description: Academic partner
    contribution_description: Harvard Medical School provides academic affiliation for Gladyshev Lab and Loscalzo Lab
  -
    name: Scipher Medicine, Inc.
    role: partner
    org_type: spinoff
    website: "https://www.sciphermedicine.com/"
    status: operational
    role_description: Spinoff company (competing interest)
    contribution_description: Scipher Medicine is a spinoff company co-founded by Albert-László Barabási and Joseph Loscalzo applying network medicine to biomarker development
  -
    name: "Brigham and Women's Hospital"
    role: primary
    org_type: institution
    website: "https://www.brighamandwomens.org/"
    status: operational
    role_description: Research collaboration partner
    contribution_description: "Brigham and Women's Hospital hosts Gladyshev Lab and Loscalzo Lab, providing aging biology expertise and network medicine guidance"
products:
  -
    name: Network Medicine Framework for Drug Repurposing Targeting Hallmarks of Aging
    type: research_methodology
    status: published
  -
    name: "SHARP: Systematic Hallmark-based Aging Repurposing Pipeline"
    type: research_methodology
    status: published
  -
    name: "SHARP: Systematic Hallmark-based Aging Repurposing Pipeline"
    type: research_methodology
    status: published
  -
    name: "SHARP: Systematic Hallmark-based Aging Repurposing Pipeline"
    type: research_methodology
    status: published
links:
  -
    url: "https://pubmed.ncbi.nlm.nih.gov/35128530/"
    type: research_publication
    title: Network Topology of Biological Aging and Geroscience-Guided Approaches to COVID-19
  -
    url: "https://pubmed.ncbi.nlm.nih.gov/35259281/"
    type: research_publication
    title: Biological mechanisms of aging predict age-related disease co-occurrence in patients
  -
    url: "https://www.nejm.org/doi/full/10.1056/NEJMp0706282"
    type: research_publication
    title: "Network Medicine - From Obesity to the 'Diseasome' - NEJM"
  -
    url: "https://www.northeastern.edu/"
    type: website
    title: Northeastern University
  -
    url: "https://hms.harvard.edu/"
    type: website
    title: Harvard Medical School
  -
    url: "https://gladyshevlab.bwh.harvard.edu/"
    type: website
    title: "Gladyshev Lab - Brigham and Women's Hospital"
  -
    url: "https://arxiv.org/abs/2509.03330"
    type: research_publication
    title: Network-driven discovery of repurposable drugs targeting hallmarks of aging - arXiv
  -
    url: "https://www.brighamandwomens.org/"
    type: website
    title: "Brigham and Women's Hospital"
  -
    url: "https://www.nature.com/articles/nrg2918"
    type: research_publication
    title: "Network Medicine: A Network-based Approach to Human Disease - Nature Reviews Genetics"
  -
    url: "https://connects.catalyst.harvard.edu/Profiles/display/Person/412"
    type: reference
    title: Joseph Loscalzo - Harvard Catalyst Profile
  -
    url: "https://www.brighamandwomens.org/research/departments/medicine/cardiovascular-medicine/loscalzo-lab"
    type: website
    title: "Loscalzo Lab - Brigham and Women's Hospital"
  -
    url: "https://en.wikipedia.org/wiki/Albert-L%C3%A1szl%C3%B3_Barab%C3%A1si"
    type: reference
    title: Albert-László Barabási - Wikipedia
  -
    url: "https://barabasi.com/"
    type: website
    title: Albert-László Barabási - Personal Website
  -
    url: "https://www.networkscienceinstitute.org/"
    type: website
    title: Network Science Institute, Northeastern University
  -
    url: "https://www.networkscienceinstitute.org/publications/network-driven-discovery-of-repurposable-drugs-targeting-hallmarks-of-aging"
    type: research_publication
    title: Network-driven discovery of repurposable drugs targeting hallmarks of aging - Network Science Institute
  -
    url: "https://scholar.google.com/citations?user=vsjWe0wAAAAJ"
    type: reference
    title: Albert-László Barabási - Google Scholar
  -
    url: "https://www.network-medicine.org/"
    type: website
    title: Network Medicine Institute
  -
    url: "https://www.brighamandwomens.org/research/departments/medicine/channing-division-of-network-medicine"
    type: website
    title: Channing Division of Network Medicine - Harvard Medical School
  -
    url: "https://arxiv.org/abs/2211.14800"
    type: research_publication
    title: Non-Coding RNAs Improve the Predictive Power of Network Medicine - arXiv
  -
    url: "https://www.embopress.org/doi/10.1038/msb4100163"
    type: research_publication
    title: Human disease classification in the postgenomic era - Molecular Systems Biology
  -
    url: "https://github.com/BnayaGross/Longevity-module"
    type: github
    title: SHARP Pipeline GitHub Repository
  -
    url: "https://clue.io/"
    type: database
    title: Connectivity Map (CMap)
  -
    url: "https://opengenes.org/"
    type: database
    title: OpenGenes Database
---

# Barabási–Gladyshev–Loscalzo Network Medicine for Hallmarks of Aging

## Description

SHARP (Systematic Hallmark-based Aging Repurposing Pipeline): Network medicine framework integrating 2,358 longevity-associated genes into human interactome (18,223 proteins, 524,156 interactions) to systematically analyze 6,442 drugs across 11 hallmarks of aging. Results: 4,809 drugs show network proximity to hallmarks (370 meet stringent z<-1.96 threshold for targeted repurposing), ~3,000 drugs per hallmark have pAGE transcriptional data, 14 pro-longevity and 14 age-accelerating drugs identified. Validation: 82.4% accuracy on clinical trials, 90.9% on mouse ITP studies. Case study: Oxymetazoline demonstrates consistent positive pAGE (1.0→0.46) across 5 network levels for altered intercellular communication.

## Mission

Network medicine approach for drug repurposing targeting hallmarks of aging using SHARP pipeline

## Project Information

**Start Date**: 2024-01-01
**Publication Date**: 2025-09-03
**Objectives**: Identify drug repurposing candidates targeting hallmarks of aging,Develop network medicine framework for systematic drug discovery,Integrate interactome proximity analysis with transcriptional reversal scoring,Provide interpretable, mechanism-based approach to drug nomination,Validate predictions against clinical trial and mouse lifespan data
**Collaboration Period**: [object Object]

## Scientific Background

```yaml
network_medicine:
  definition: Network medicine views diseases as perturbations of complex intracellular and intercellular networks
  key_principles:
  - Diseases are network perturbations, not single-gene defects
  - Disease modules represent functionally related genes
  - Network proximity predicts drug-disease associations
  historical_context: Pioneered by Barabási, Loscalzo, and colleagues in 2007-2011
hallmarks_of_aging:
  list:
  - Genomic instability
  - Telomere attrition
  - Epigenetic alterations
  - Loss of proteostasis
  - Deregulated nutrient sensing
  - Mitochondrial dysfunction
  - Cellular senescence
  - Stem cell exhaustion
  - Altered intercellular communication
  - Disabled macroautophagy
  - Changes in extracellular matrix
  count: 11
  definition: Key biological processes associated with aging
```

## Lessons Learned

### Achievements

- Developed SHARP pipeline for systematic drug repurposing
- Identified 370 drug candidates targeting 11 hallmarks
- Achieved 82.4% accuracy on clinical trial drugs
- Achieved 90.9% accuracy on mouse lifespan compounds
- Demonstrated TP53 as key hub gene across hallmarks

### Impact on Field

SHARP provides interpretable, mechanism-based framework for drug repurposing targeting multiple hallmarks of aging with validated 82-91% accuracy, enabling systematic multi-hallmark intervention design.

## Organizations

### Network Science Institute, Northeastern University
**Role in Project**: primary
**Role Description**: Primary development institution
**Contribution**: Network Science Institute hosts Barabási Lab which developed SHARP pipeline and led computational framework implementation
**Organization Type**: research_center
**Status**: operational
**Website**: https://www.networkscienceinstitute.org/
**Description**: Research institute focused on network science and network medicine
**Focus**: Network science, network medicine, complex systems

### Harvard Medical School
**Role in Project**: primary
**Role Description**: Academic partner
**Contribution**: Harvard Medical School provides academic affiliation for Gladyshev Lab and Loscalzo Lab
**Organization Type**: institution
**Status**: operational
**Website**: https://hms.harvard.edu/
**Description**: Graduate medical school of Harvard University
**Focus**: Medical education, biomedical research, aging research

### Scipher Medicine, Inc.
**Role in Project**: partner
**Role Description**: Spinoff company (competing interest)
**Contribution**: Scipher Medicine is a spinoff company co-founded by Albert-László Barabási and Joseph Loscalzo applying network medicine to biomarker development
**Organization Type**: spinoff
**Status**: operational
**Website**: https://www.sciphermedicine.com/
**Description**: Company applying network medicine strategies to biomarker development and personalized drug selection. Co-founded by Albert-László Barabási and Joseph Loscalzo.
**Focus**: Network medicine, biomarker development, personalized drug selection

### Brigham and Women's Hospital
**Role in Project**: primary
**Role Description**: Research collaboration partner
**Contribution**: Brigham and Women's Hospital hosts Gladyshev Lab and Loscalzo Lab, providing aging biology expertise and network medicine guidance
**Organization Type**: institution
**Status**: operational
**Website**: https://www.brighamandwomens.org/
**Description**: Teaching hospital of Harvard Medical School, major research institution
**Focus**: Clinical care, biomedical research, aging research

## Locations

### Harvard Medical School
**Type**: institution
**City**: Boston
**State/Region**: Massachusetts
**Country**: USA
**Organizations**: Harvard Medical School

### Brigham and Women's Hospital
**Type**: institution
**City**: Boston
**State/Region**: Massachusetts
**Country**: USA
**Organizations**: Brigham and Women's Hospital

### Network Science Institute, Northeastern University
**Type**: institution
**City**: Boston
**State/Region**: Massachusetts
**Country**: USA
**Organizations**: Network Science Institute, Northeastern University

### Harvard Medical School
**Type**: institution
**City**: Boston
**State/Region**: Massachusetts
**Country**: USA
**Organizations**: Harvard Medical School

### Brigham and Women's Hospital
**Type**: institution
**City**: Boston
**State/Region**: Massachusetts
**Country**: USA
**Organizations**: Brigham and Women's Hospital

### Network Science Institute, Northeastern University
**Type**: institution
**City**: Boston
**State/Region**: Massachusetts
**Country**: USA
**Organizations**: Network Science Institute, Northeastern University

### Harvard Medical School
**Type**: institution
**City**: Boston
**State/Region**: Massachusetts
**Country**: USA
**Organizations**: Harvard Medical School

### Brigham and Women's Hospital
**Type**: institution
**City**: Boston
**State/Region**: Massachusetts
**Country**: USA
**Organizations**: Brigham and Women's Hospital

### Network Science Institute, Northeastern University
**Type**: institution
**City**: Boston
**State/Region**: Massachusetts
**Country**: USA
**Organizations**: Network Science Institute, Northeastern University

### Harvard Medical School
**Type**: institution
**City**: Boston
**State/Region**: Massachusetts
**Country**: USA
**Organizations**: Harvard Medical School

### Brigham and Women's Hospital
**Type**: institution
**City**: Boston
**State/Region**: Massachusetts
**Country**: USA
**Organizations**: Brigham and Women's Hospital

### Network Science Institute, Northeastern University
**Type**: institution
**City**: Boston
**State/Region**: Massachusetts
**Country**: USA
**Organizations**: Network Science Institute, Northeastern University

## Products

### Network Medicine Framework for Drug Repurposing Targeting Hallmarks of Aging
**Type**: research_methodology
**Status**: published
**Role in Project**: primary
**Relationship Description**: Primary research methodology developed in this collaboration: Network Medicine Framework for Drug Repurposing Targeting Hallmarks of Aging
**Description**: Network medicine framework integrating longevity-associated genes into human interactome for systematic drug repurposing targeting hallmarks of aging. Combines interactome proximity analysis with transcriptional reversal scoring (pAGE) to identify drug candidates.
**Technical Details**:
```yaml
overview: Network medicine framework integrating 2,358 longevity-associated genes into the human interactome to identify existing drugs capable of modulating aging processes
components:
  -
    name: Interactome Proximity Analysis
    description: Integration of longevity-associated genes into human protein-protein interaction network to measure proximity of compounds to hallmark modules
    technical_details:
    interpretation: Drugs with targets closer to hallmark modules are more likely to modulate those aging processes
    proximity_metric: Network distance between drug targets and hallmark module genes
    calculation_method: Shortest path distance or random walk-based proximity in the protein-protein interaction network
  -
    name: Transcriptional Reversal Score (pAGE)
    description: Transcription-based metric that evaluates whether drug-induced expression shifts enhance or counteract known age-related expression changes
    technical_details:
    calculation: Correlation-based metric comparing drug-induced expression changes with age-related expression patterns
    interpretation: Higher pAGE scores indicate drugs that more effectively reverse age-related transcriptional changes
    formula_concept: pAGE measures the correlation between drug-induced expression shifts and age-related expression changes. Positive values indicate reversal of age-related patterns
  -
    name: Hallmark Module Mapping
    description: Systematic mapping of drugs to hallmark modules based on network proximity and transcriptional reversal
    technical_details:
    interpretability: Drug-hallmark associations include identified molecular pathways and mechanisms
    mapping_approach: Each drug is mapped to hallmark modules based on proximity of its targets to module genes and pAGE score
    module_definition: Connected subgraph of genes associated with a specific hallmark of aging
data_sources:
  drug_data:
  count: 6442
  sources: DrugBank, ChEMBL, clinical trial databases
  interactome: Human protein-protein interaction network (STRING, BioGRID, IntAct, HumanNet)
  longevity_genes:
  count: 2358
  sources: Literature curation, aging databases, hallmark-specific gene sets
  transcriptomic_data:
  aging_expression: GTEx, GEO datasets with age-stratified expression data
  drug_perturbation: LINCS, Connectivity Map, or similar drug perturbation expression datasets
step_by_step_process:
  -
    name: Gene Collection and Curation
    step: 1
    description: Collection of 2,358 longevity-associated genes from literature and databases
  -
    name: Interactome Construction
    step: 2
    description: Integration of longevity genes into human protein-protein interaction network
  -
    name: Hallmark Module Identification
    step: 3
    description: Identification of connected subgraphs (modules) for each hallmark of aging
  -
    name: Drug Target Mapping
    step: 4
    description: Mapping of 6,442 compounds to their protein targets in the interactome
  -
    name: Network Proximity Calculation
    step: 5
    description: Calculation of proximity between drug targets and hallmark modules
  -
    name: Transcriptional Data Integration
    step: 6
    description: Integration of drug-induced gene expression data and age-related expression patterns
  -
    name: pAGE Score Calculation
    step: 7
    description: Calculation of transcriptional reversal score (pAGE) for each drug
  -
    name: Metric Integration and Ranking
    step: 8
    description: Integration of network proximity and pAGE scores to rank drug candidates
  -
    name: Mechanism Identification
    step: 9
    description: Identification of molecular mechanisms for each drug-hallmark association
```

### SHARP: Systematic Hallmark-based Aging Repurposing Pipeline
**Type**: research_methodology
**Status**: published
**Role in Project**: primary
**Relationship Description**: SHARP: Systematic Hallmark-based Aging Repurposing Pipeline - primary research methodology developed in this collaboration
**Description**: Network medicine framework integrating 2,358 longevity-associated genes into human interactome (18,223 proteins, 524,156 interactions) for systematic drug repurposing targeting 11 hallmarks of aging. Analyzed 6,442 drugs: 4,809 show network proximity (370 meet stringent z<-1.96 threshold), ~3,000 per hallmark have pAGE data. Validation: 82.4% clinical trial accuracy, 90.9% mouse lifespan accuracy.
**Technical Details**:
```yaml
key_gene:
  name: TP53
  role: Most connected gene across aging hallmarks
  hallmarks_associated: 7
validation:
  status: Computationally validated with high accuracy
  known_drugs:
  aspirin:
  hallmarks: 6
  page_note: Positive pAGE for multiple hallmarks
  dasatinib:
  note: Known senolytic
  hallmarks: 5
  sirolimus:
  note: mTOR inhibitor
  hallmarks: 1
  clinical_trials:
  note: 16 of 17 drugs show significant or marginal proximity
  accuracy: 82.4%
  capture_rate: 94%
  drugs_missed: 1
  drugs_tested: 17
  drugs_captured: 16
  page_validation:
  insight: All 25 clinically validated drugs (17 clinical trials + 11 ITP with overlap) show positive pAGE for minimum of 4 hallmarks
  significance: Demonstrates pAGE metric successfully identifies anti-aging drugs
  total_validated_drugs: 25
  itp_mouse_lifespan:
  accuracy: 90.9%
  capture_rate: 91%
  drugs_missed: 1
  drugs_tested: 11
  drugs_captured: 10
key_metrics:
  pAGE:
  range: -1 to +1
  formula: "pAGE = -(1/|Λ∅|) × Σ(i∈Λ) σi × σ''i"
  full_name: Pro-Age Score
  interpretation:
  neutral: No effect (pAGE = 0)
  negative: Age-accelerating - exacerbates age-related changes (pAGE < 0)
  positive: Pro-longevity - reverses age-related expression (pAGE > 0)
  formula_components:
  sigma_i: Drug-induced expression change (-1, 0, +1)
  lambda_zero: "Normalization factor: Λ∅ = {i | σi × σ''i ≠ 0}"
  sigma_prime_i: Age-related expression change (-1, +1)
  network_proximity:
  formula: P(S,T) = (1/||T||) × Σ(t∈T) min(s∈S) d(s,t)
  formula_components:
  S: Set of drug target proteins
  T: Set of hallmark module genes
  d_st: Shortest path distance between genes s and t in interactome
  significance_thresholds:
  validation_method: Compared with 1,000 random gene samples preserving size and degree distribution
  marginally_significant: z-score < -1.645
  statistically_significant: z-score < -1.96 (p < 0.05)
  network_separation:
  formula: S(A,B) = ⟨d_AB⟩ - (⟨d_AA⟩ + ⟨d_BB⟩)/2
  purpose: Assess topological overlap between hallmark modules
  interpretation:
  negative: Overlapping modules
  positive: Distinct modules
data_sources:
  drug_data: DrugBank
  longevity_genes: OpenGenes Database
  perturbation_data:
  url: "https://clue.io/"
  database: Connectivity Map (CMap)
  cell_line: MCF7
  gene_disease_associations:
  - ClinGen
  - ClinVar
  - CTD
  - DisGeNET
  - GWAS Catalog
  - OMIM
  - Orphanet
  - PheGenI
  - PsyGeNet
pipeline_name: SHARP
code_repository: "https://github.com/BnayaGross/Longevity-module"
hallmark_modules:
  -
    genes: 89
    z_score: 1.67
    hallmark: Epigenetic alterations
  -
    genes: 53
    hallmark: Altered intercellular communication
    significance: significant
  -
    genes: 49
    hallmark: Genomic instability
    significance: significant
  -
    genes: 40
    hallmark: Mitochondrial dysfunction
    significance: significant
  -
    genes: 34
    hallmark: Deregulated nutrient sensing
    significance: significant
  -
    genes: 27
    hallmark: Cell senescence
    significance: significant
  -
    genes: 27
    z_score: 1.74
    hallmark: Loss of proteostasis
  -
    genes: 16
    hallmark: Telomere attrition
    significance: significant
  -
    genes: 10
    hallmark: Exhaustion of stem cells
    significance: significant
  -
    genes: 7
    hallmark: Disabled macroautophagy
    significance: significant
  -
    genes: 7
    hallmark: Changes in extracellular matrix
    significance: significant
longevity_vector:
  total_genes: 2025
  up_regulated_with_age: 995
  down_regulated_with_age: 1030
methodology_steps:
  - Gene collection from OpenGenes (2,358 genes)
  - Interactome construction (18,223 proteins, 524,156 interactions)
  - Hallmark module identification (11 modules, LCC analysis)
  - Drug target mapping (6,442 compounds from DrugBank)
  - Network proximity calculation
  - Longevity vector construction (2,025 genes)
  - Drug perturbation signature extraction (CMap, MCF7)
  - pAGE score calculation
  - Integration and drug ranking
  - Mechanism identification
pipeline_full_name: Systematic Hallmark-based Aging Repurposing Pipeline
quantitative_results:
  longevity_genes: 2358
  hallmark_coverage:
  cell_senescence: 1693
  telomere_attrition: 1421
  genomic_instability: 1755
  loss_of_proteostasis: 1890
  epigenetic_alterations: 2340
  disabled_macroautophagy: 1609
  exhaustion_of_stem_cells: 1670
  mitochondrial_dysfunction: 1982
  deregulated_nutrient_sensing: 1758
  extracellular_matrix_changes: 1677
  altered_intercellular_communication: 2847
  compounds_analyzed: 6442
  hallmarks_of_aging: 11
  pro_longevity_drugs: 14
  binding_interactions: 524156
  age_accelerating_drugs: 14
  data_scale_explanation: 4,809 of 6,442 drugs (74.6%) show network proximity to at least one hallmark. The 370 drugs represent those meeting stringent statistical significance threshold (z-score < -1.96) for priority experimental validation. Approximately 3,000 drugs per hallmark have pAGE transcriptional reversal data from Connectivity Map.
  inconsistent_page_drugs: 32
  proteins_in_interactome: 18223
  drugs_with_any_proximity: 4809
  drugs_with_page_data_per_hallmark: 3000
  validation_accuracy_mouse_lifespan: 90.9%
  validation_accuracy_clinical_trials: 82.4%
  drugs_with_stringent_proximity_threshold: 370
statistical_insights:
  page_coverage:
  note: pAGE requires drug perturbation expression data from Connectivity Map
  cell_line: MCF7
  limitation: Tissue-specific - may not generalize to all cell types
  drugs_with_page_per_hallmark: approximately 3,000
  proximity_coverage:
  lowest_coverage: Telomere attrition (1,421 drugs)
  highest_coverage: Altered intercellular communication (2,847 drugs)
  per_hallmark_range: 1,421-2,847 drugs
  coverage_percentage: 74.6%
  total_drugs_analyzed: 6442
  drugs_with_any_proximity: 4809
  multi_hallmark_insights:
  interpretation: Most drugs are hallmark-specific. 270 drugs show broad anti-aging potential across 6+ hallmarks, making them candidates for multi-hallmark interventions.
  dual_target_drugs: 808
  single_target_drugs: 978
  triple_target_drugs: 555
  broad_spectrum_6plus: 270
  significance_thresholds:
  page: Positive values indicate anti-aging; z > 1.96 for significance
  proximity: z-score < -1.96 for p < 0.05
  combined_criteria: Both metrics integrated for final ranking
hallmark_specific_drugs:
  note: "From CSV analysis: Each hallmark has 1,400-2,800+ drugs with proximity data. Listed below are top candidates with positive pAGE."
  cell_senescence:
  with_page_data: 3
  drugs_with_page_data: 3000
  total_with_proximity: 1693
  drugs_with_significant_proximity: 27
  telomere_attrition:
  drugs_with_page_data: 3000
  total_with_proximity: 1421
  genomic_instability:
  drugs_with_page_data: 3000
  total_with_proximity: 1755
  loss_of_proteostasis:
  drugs_with_page_data: 3000
  total_with_proximity: 1890
  epigenetic_alterations:
  drugs_with_page_data: 3000
  total_with_proximity: 2340
  positive_pAGE_examples:
  - clinofibrate
  drugs_with_significant_proximity: 52
  disabled_macroautophagy:
  drugs_with_page_data: 3000
  total_with_proximity: 1609
  positive_pAGE_examples:
  - imexon
  drugs_with_significant_proximity: 7
  exhaustion_of_stem_cells:
  drugs_with_page_data: 3000
  total_with_proximity: 1670
  positive_pAGE_examples:
  - guanadrel
  - nisoxetine
  - amineptine
  - amlexanox
  drugs_with_significant_proximity: 113
  mitochondrial_dysfunction:
  examples_levels_4_5:
  -
  drug: navitoclax
  class: senolytic
  -
  drug: alsterpaullone
  class: CDK inhibitor
  -
  drug: pyrazolanthrone
  class: JNK inhibitor
  drugs_with_page_data: 3000
  total_with_proximity: 1982
  drugs_with_significant_proximity: 21
  deregulated_nutrient_sensing:
  with_page_data: 4
  positive_at_level_4: 3
  drugs_with_page_data: 3000
  total_with_proximity: 1758
  drugs_with_significant_proximity: 52
  extracellular_matrix_changes:
  results:
  -
  drug: marimastat
  pAGE: positive
  -
  drug: captopril
  pAGE: negative
  drugs_with_page_data: 3000
  total_with_proximity: 1677
  drugs_with_significant_proximity: 25
  altered_intercellular_communication:
  drugs_with_page_data: 3038
  total_with_proximity: 2847
  positive_pAGE_top_drugs:
  - oxymetazoline
  - metaraminol
  - terazosin
  - tamsulosin
  - tetryzoline
  - cirazoline
  - synephrine
  drugs_with_significant_proximity: 61
case_study_oxymetazoline:
  drug: Oxymetazoline
  targets:
  serotonin:
  - HTR1A
  - HTR1B
  - HTR1D
  target_details:
  HTR1B: Nearest neighbor to hallmark module
  ADRA1A: Both drug target AND hallmark module gene
  ADRA1B: Nearest neighbor to hallmark module
  alpha1_adrenergic:
  - ADRA1A
  - ADRA1B
  - ADRA1D
  hallmark: Altered intercellular communication
  interpretation: Consistent positive pAGE across all 5 network proximity levels, with peak significance at level 4 (z=2.35). Demonstrates robust anti-aging signal through multiple layers of protein interaction network. Network topology reveals both direct module membership (ADRA1A) and propagation through hub genes (TP53).
  proximity_count: 5
  network_topology:
  path_note: Perturbation propagates through bypass path (not shortest path via ALB/NR3C1), demonstrating network effects beyond direct targets
  direct_connections:
  alpha1_receptors: Connect to module via ALB and NR3C1
  serotonin_receptors: Connect to module via TGFB1
  actual_perturbation_path:
  - ACKR3
  - NFKB1
  - TP53
  - AKT1
  pAGE_progression:
  level_1:
  pAGE: 1
  z_score: 1.73
  strength: strongest
  level_2:
  pAGE: 0.714
  z_score: 1.89
  strength: strong
  level_3:
  pAGE: 0.556
  z_score: 1.67
  strength: moderate
  level_4:
  pAGE: 0.462
  z_score: 2.35
  strength: strong
  level_5:
  pAGE: 0.135
  z_score: 1.88
  strength: mild
  proximity_levels:
  - 1
  - 2
  - 3
  - 4
  - 5
  mechanism_pathway:
  - ACKR3
  - NFKB1
  - TP53
  - AKT1
  network_proximity: 1.5
multi_hallmark_targeting:
  insight: Most drugs target 1-2 hallmarks (1,786 drugs). 270 drugs target 6+ hallmarks, suggesting broad-spectrum anti-aging potential.
  distribution:
  1_hallmark: 978
  2_hallmarks: 808
  3_hallmarks: 555
  4_hallmarks: 434
  5_hallmarks: 305
  6_hallmarks: 270
  7_hallmarks: 104
  8_hallmarks: 102
  9_hallmarks: 80
  10_hallmarks: 59
  11_hallmarks: 70
  12_plus_hallmarks: 44
  multi_target_count: 3831
  single_target_count: 978
  broad_spectrum_6plus: 270
  total_drugs_analyzed: 4809
```

### SHARP: Systematic Hallmark-based Aging Repurposing Pipeline
**Type**: research_methodology
**Status**: published
**Role in Project**: primary
**Relationship Description**: SHARP: Systematic Hallmark-based Aging Repurposing Pipeline - primary research methodology developed in this collaboration
**Description**: Network medicine framework integrating 2,358 longevity-associated genes into human interactome (18,223 proteins, 524,156 interactions) for systematic drug repurposing targeting 11 hallmarks of aging. Combines interactome proximity analysis with transcriptional reversal scoring (pAGE) to identify 370 drug candidates with 82.4% clinical trial accuracy and 90.9% mouse lifespan accuracy.
**Technical Details**:
```yaml
key_gene:
  name: TP53
  role: Most connected gene across aging hallmarks
  hallmarks_associated: 7
validation:
  known_drugs:
  aspirin:
  hallmarks: 6
  dasatinib:
  hallmarks: 5
  sirolimus:
  hallmarks: 1
  clinical_trials:
  accuracy: 82.4%
  drugs_tested: 17
  drugs_captured: 16
  itp_mouse_lifespan:
  accuracy: 90.9%
  drugs_tested: 11
  drugs_captured: 10
key_metrics:
  pAGE:
  range: -1 to +1
  formula: "pAGE = -(1/|Λ∅|) × Σ(i∈Λ) σi × σ''i"
  full_name: Pro-Age Score
  interpretation:
  negative: Age-accelerating - exacerbates age-related changes
  positive: Pro-longevity - reverses age-related expression
  network_proximity:
  formula: P(S,T) = (1/||T||) × Σ(t∈T) min(s∈S) d(s,t)
  significance_threshold: z-score < -1.96
data_sources:
  drug_data: DrugBank
  longevity_genes: OpenGenes Database
  perturbation_data:
  url: "https://clue.io/"
  database: Connectivity Map (CMap)
  cell_line: MCF7
  gene_disease_associations:
  - ClinGen
  - ClinVar
  - CTD
  - DisGeNET
  - GWAS Catalog
  - OMIM
  - Orphanet
  - PheGenI
  - PsyGeNet
pipeline_name: SHARP
code_repository: "https://github.com/BnayaGross/Longevity-module"
hallmark_modules:
  -
    genes: 89
    z_score: 1.67
    hallmark: Epigenetic alterations
  -
    genes: 53
    hallmark: Altered intercellular communication
    significance: significant
  -
    genes: 49
    hallmark: Genomic instability
    significance: significant
  -
    genes: 40
    hallmark: Mitochondrial dysfunction
    significance: significant
  -
    genes: 34
    hallmark: Deregulated nutrient sensing
    significance: significant
  -
    genes: 27
    hallmark: Cell senescence
    significance: significant
  -
    genes: 27
    z_score: 1.74
    hallmark: Loss of proteostasis
  -
    genes: 16
    hallmark: Telomere attrition
    significance: significant
  -
    genes: 10
    hallmark: Exhaustion of stem cells
    significance: significant
  -
    genes: 7
    hallmark: Disabled macroautophagy
    significance: significant
  -
    genes: 7
    hallmark: Changes in extracellular matrix
    significance: significant
longevity_vector:
  total_genes: 2025
  up_regulated_with_age: 995
  down_regulated_with_age: 1030
methodology_steps:
  - Gene collection from OpenGenes (2,358 genes)
  - Interactome construction (18,223 proteins, 524,156 interactions)
  - Hallmark module identification (11 modules, LCC analysis)
  - Drug target mapping (6,442 compounds from DrugBank)
  - Network proximity calculation
  - Longevity vector construction (2,025 genes)
  - Drug perturbation signature extraction (CMap, MCF7)
  - pAGE score calculation
  - Integration and drug ranking
  - Mechanism identification
pipeline_full_name: Systematic Hallmark-based Aging Repurposing Pipeline
quantitative_results:
  longevity_genes: 2358
  compounds_analyzed: 6442
  hallmarks_of_aging: 11
  pro_longevity_drugs: 14
  binding_interactions: 524156
  drugs_with_cmap_data: 60
  age_accelerating_drugs: 14
  inconsistent_page_drugs: 32
  proteins_in_interactome: 18223
  drugs_with_significant_proximity: 370
  validation_accuracy_mouse_lifespan: 90.9%
  validation_accuracy_clinical_trials: 82.4%
hallmark_specific_drugs:
  epigenetic_alterations:
  total: 52
  with_cmap: 5
  positive_pAGE:
  - clinofibrate
  disabled_macroautophagy:
  total: 7
  with_cmap: 2
  positive_pAGE:
  - imexon
  exhaustion_of_stem_cells:
  total: 113
  with_cmap: 19
  positive_pAGE:
  - guanadrel
  - nisoxetine
  - amineptine
  - amlexanox
  extracellular_matrix_changes:
  total: 25
  results:
  -
  drug: marimastat
  pAGE: positive
  -
  drug: captopril
  pAGE: negative
  with_cmap: 2
  altered_intercellular_communication:
  total: 61
  with_cmap: 25
  positive_pAGE:
  - oxymetazoline
  - metaraminol
  - terazosin
  - tamsulosin
  - tetryzoline
  - cirazoline
  - synephrine
case_study_oxymetazoline:
  drug: Oxymetazoline
  pAGE: 0.46
  targets:
  serotonin:
  - HTR1A
  - HTR1B
  - HTR1D
  alpha1_adrenergic:
  - ADRA1A
  - ADRA1B
  - ADRA1D
  hallmark: Altered intercellular communication
  proximity: 1.5
  pAGE_z_score: 2.35
  mechanism_pathway:
  - ACKR3
  - NFKB1
  - TP53
  - AKT1
```

### SHARP: Systematic Hallmark-based Aging Repurposing Pipeline
**Type**: research_methodology
**Status**: published
**Role in Project**: primary
**Relationship Description**: SHARP: Systematic Hallmark-based Aging Repurposing Pipeline - primary research methodology developed in this collaboration
**Description**: Network medicine framework integrating 2,358 longevity-associated genes into human interactome (18,223 proteins, 524,156 interactions) for systematic drug repurposing targeting 11 hallmarks of aging. Analyzed 6,442 drugs: 4,809 show network proximity (370 meet stringent z<-1.96 threshold), ~3,000 per hallmark have pAGE data. Validation: 82.4% clinical trial accuracy, 90.9% mouse lifespan accuracy.
**Technical Details**:
```yaml
key_gene:
  name: TP53
  role: Most connected gene across aging hallmarks
  hallmarks_associated: 7
validation:
  status: Computationally validated with high accuracy
  known_drugs:
  aspirin:
  hallmarks: 6
  dasatinib:
  hallmarks: 5
  sirolimus:
  hallmarks: 1
  clinical_trials:
  accuracy: 82.4%
  drugs_tested: 17
  drugs_captured: 16
  itp_mouse_lifespan:
  accuracy: 90.9%
  drugs_tested: 11
  drugs_captured: 10
key_metrics:
  pAGE:
  range: -1 to +1
  formula: "pAGE = -(1/|Λ∅|) × Σ(i∈Λ) σi × σ''i"
  full_name: Pro-Age Score
  interpretation:
  negative: Age-accelerating - exacerbates age-related changes
  positive: Pro-longevity - reverses age-related expression
  network_proximity:
  formula: P(S,T) = (1/||T||) × Σ(t∈T) min(s∈S) d(s,t)
  significance_threshold: z-score < -1.96
data_sources:
  drug_data: DrugBank
  longevity_genes: OpenGenes Database
  perturbation_data:
  url: "https://clue.io/"
  database: Connectivity Map (CMap)
  cell_line: MCF7
  gene_disease_associations:
  - ClinGen
  - ClinVar
  - CTD
  - DisGeNET
  - GWAS Catalog
  - OMIM
  - Orphanet
  - PheGenI
  - PsyGeNet
pipeline_name: SHARP
code_repository: "https://github.com/BnayaGross/Longevity-module"
hallmark_modules:
  -
    genes: 89
    z_score: 1.67
    hallmark: Epigenetic alterations
  -
    genes: 53
    hallmark: Altered intercellular communication
    significance: significant
  -
    genes: 49
    hallmark: Genomic instability
    significance: significant
  -
    genes: 40
    hallmark: Mitochondrial dysfunction
    significance: significant
  -
    genes: 34
    hallmark: Deregulated nutrient sensing
    significance: significant
  -
    genes: 27
    hallmark: Cell senescence
    significance: significant
  -
    genes: 27
    z_score: 1.74
    hallmark: Loss of proteostasis
  -
    genes: 16
    hallmark: Telomere attrition
    significance: significant
  -
    genes: 10
    hallmark: Exhaustion of stem cells
    significance: significant
  -
    genes: 7
    hallmark: Disabled macroautophagy
    significance: significant
  -
    genes: 7
    hallmark: Changes in extracellular matrix
    significance: significant
longevity_vector:
  total_genes: 2025
  up_regulated_with_age: 995
  down_regulated_with_age: 1030
methodology_steps:
  - Gene collection from OpenGenes (2,358 genes)
  - Interactome construction (18,223 proteins, 524,156 interactions)
  - Hallmark module identification (11 modules, LCC analysis)
  - Drug target mapping (6,442 compounds from DrugBank)
  - Network proximity calculation
  - Longevity vector construction (2,025 genes)
  - Drug perturbation signature extraction (CMap, MCF7)
  - pAGE score calculation
  - Integration and drug ranking
  - Mechanism identification
pipeline_full_name: Systematic Hallmark-based Aging Repurposing Pipeline
quantitative_results:
  longevity_genes: 2358
  hallmark_coverage:
  cell_senescence: 1693
  telomere_attrition: 1421
  genomic_instability: 1755
  loss_of_proteostasis: 1890
  epigenetic_alterations: 2340
  disabled_macroautophagy: 1609
  exhaustion_of_stem_cells: 1670
  mitochondrial_dysfunction: 1982
  deregulated_nutrient_sensing: 1758
  extracellular_matrix_changes: 1677
  altered_intercellular_communication: 2847
  compounds_analyzed: 6442
  hallmarks_of_aging: 11
  pro_longevity_drugs: 14
  binding_interactions: 524156
  age_accelerating_drugs: 14
  data_scale_explanation: 4,809 of 6,442 drugs (74.6%) show network proximity to at least one hallmark. The 370 drugs represent those meeting stringent statistical significance threshold (z-score < -1.96) for priority experimental validation. Approximately 3,000 drugs per hallmark have pAGE transcriptional reversal data from Connectivity Map.
  inconsistent_page_drugs: 32
  proteins_in_interactome: 18223
  drugs_with_any_proximity: 4809
  drugs_with_page_data_per_hallmark: 3000
  validation_accuracy_mouse_lifespan: 90.9%
  validation_accuracy_clinical_trials: 82.4%
  drugs_with_stringent_proximity_threshold: 370
statistical_insights:
  page_coverage:
  note: pAGE requires drug perturbation expression data from Connectivity Map
  cell_line: MCF7
  limitation: Tissue-specific - may not generalize to all cell types
  drugs_with_page_per_hallmark: approximately 3,000
  proximity_coverage:
  lowest_coverage: Telomere attrition (1,421 drugs)
  highest_coverage: Altered intercellular communication (2,847 drugs)
  per_hallmark_range: 1,421-2,847 drugs
  coverage_percentage: 74.6%
  total_drugs_analyzed: 6442
  drugs_with_any_proximity: 4809
  multi_hallmark_insights:
  interpretation: Most drugs are hallmark-specific. 270 drugs show broad anti-aging potential across 6+ hallmarks, making them candidates for multi-hallmark interventions.
  dual_target_drugs: 808
  single_target_drugs: 978
  triple_target_drugs: 555
  broad_spectrum_6plus: 270
  significance_thresholds:
  page: Positive values indicate anti-aging; z > 1.96 for significance
  proximity: z-score < -1.96 for p < 0.05
  combined_criteria: Both metrics integrated for final ranking
hallmark_specific_drugs:
  note: "From CSV analysis: Each hallmark has 1,400-2,800+ drugs with proximity data. Listed below are top candidates with positive pAGE."
  cell_senescence:
  drugs_with_page_data: 3000
  total_with_proximity: 1693
  telomere_attrition:
  drugs_with_page_data: 3000
  total_with_proximity: 1421
  genomic_instability:
  drugs_with_page_data: 3000
  total_with_proximity: 1755
  loss_of_proteostasis:
  drugs_with_page_data: 3000
  total_with_proximity: 1890
  epigenetic_alterations:
  drugs_with_page_data: 3000
  total_with_proximity: 2340
  positive_pAGE_examples:
  - clinofibrate
  drugs_with_significant_proximity: 52
  disabled_macroautophagy:
  drugs_with_page_data: 3000
  total_with_proximity: 1609
  positive_pAGE_examples:
  - imexon
  drugs_with_significant_proximity: 7
  exhaustion_of_stem_cells:
  drugs_with_page_data: 3000
  total_with_proximity: 1670
  positive_pAGE_examples:
  - guanadrel
  - nisoxetine
  - amineptine
  - amlexanox
  drugs_with_significant_proximity: 113
  mitochondrial_dysfunction:
  drugs_with_page_data: 3000
  total_with_proximity: 1982
  deregulated_nutrient_sensing:
  drugs_with_page_data: 3000
  total_with_proximity: 1758
  extracellular_matrix_changes:
  results:
  -
  drug: marimastat
  pAGE: positive
  -
  drug: captopril
  pAGE: negative
  drugs_with_page_data: 3000
  total_with_proximity: 1677
  drugs_with_significant_proximity: 25
  altered_intercellular_communication:
  drugs_with_page_data: 3038
  total_with_proximity: 2847
  positive_pAGE_top_drugs:
  - oxymetazoline
  - metaraminol
  - terazosin
  - tamsulosin
  - tetryzoline
  - cirazoline
  - synephrine
  drugs_with_significant_proximity: 61
case_study_oxymetazoline:
  drug: Oxymetazoline
  targets:
  serotonin:
  - HTR1A
  - HTR1B
  - HTR1D
  alpha1_adrenergic:
  - ADRA1A
  - ADRA1B
  - ADRA1D
  hallmark: Altered intercellular communication
  interpretation: Consistent positive pAGE across all 5 network proximity levels, with peak significance at level 4 (z=2.35). Demonstrates robust anti-aging signal through multiple layers of protein interaction network.
  proximity_count: 5
  pAGE_progression:
  level_1:
  pAGE: 1
  z_score: 1.73
  strength: strongest
  level_2:
  pAGE: 0.714
  z_score: 1.89
  strength: strong
  level_3:
  pAGE: 0.556
  z_score: 1.67
  strength: moderate
  level_4:
  pAGE: 0.462
  z_score: 2.35
  strength: strong
  level_5:
  pAGE: 0.135
  z_score: 1.88
  strength: mild
  proximity_levels:
  - 1
  - 2
  - 3
  - 4
  - 5
  mechanism_pathway:
  - ACKR3
  - NFKB1
  - TP53
  - AKT1
multi_hallmark_targeting:
  insight: Most drugs target 1-2 hallmarks (1,786 drugs). 270 drugs target 6+ hallmarks, suggesting broad-spectrum anti-aging potential.
  distribution:
  1_hallmark: 978
  2_hallmarks: 808
  3_hallmarks: 555
  4_hallmarks: 434
  5_hallmarks: 305
  6_hallmarks: 270
  7_hallmarks: 104
  8_hallmarks: 102
  9_hallmarks: 80
  10_hallmarks: 59
  11_hallmarks: 70
  12_plus_hallmarks: 44
  multi_target_count: 3831
  single_target_count: 978
  broad_spectrum_6plus: 270
  total_drugs_analyzed: 4809
```

## Key People

### Joseph Ehlert
**Title**: Researcher
**Participation Type**: researcher
**Role in Project**: Co-author
**Affiliations**: Network Science Institute, Northeastern University, Barabási Lab
**Involvement Period**: {"end":null,"start":"2024-01","status":"ongoing"}
**Contribution**: Co-author contributing to writing - review & editing. No competing interests.
**Expertise**: Network science, Computational biology
**Biography**: Researcher at Barabási Lab, contributing to network analysis and computational methods

### Bnaya Gross
**Title**: Researcher
**Participation Type**: researcher
**Role in Project**: Lead Researcher, First Author
**Affiliations**: Network Science Institute, Northeastern University, Barabási Lab
**Involvement Period**: {"end":null,"start":"2024-01","status":"ongoing"}
**Responsibilities**:
- Conceptualization
- Methodology
- Investigation
- Visualization
- Writing - original draft
- Writing - review & editing
**Contribution**: Lead researcher and first author. Developed SHARP pipeline methodology. Fulbright Postdoctoral Fellow. No competing interests.
**Expertise**: Network science, Network medicine, Drug repurposing, Computational biology
**Biography**: Lead researcher and first author of the publication. Member of Barabási Lab at Network Science Institute, Northeastern University. Fulbright Postdoctoral Fellow.

### Joseph Loscalzo
**Title**: Hersey Professor of the Theory and Practice of Medicine, Chairman of the Department of Medicine
**Participation Type**: pi
**Role in Project**: Co-Principal Investigator
**Affiliations**: Brigham and Women's Hospital, Harvard Medical School, Loscalzo Lab
**Involvement Period**: {"end":null,"start":"2024-01","status":"ongoing"}
**Responsibilities**:
- Network medicine expertise
- Clinical translation guidance
- Supervision
- Writing - review & editing
**Contribution**: Co-Principal Investigator providing network medicine expertise. Co-founder of Scipher Medicine (competing interest).
**Expertise**: Network medicine, Cardiovascular medicine, Systems biology, Complex disease networks, Drug repurposing
**Biography**: Hersey Professor of the Theory and Practice of Medicine and Chairman of the Department of Medicine at Brigham and Women's Hospital, Harvard Medical School. Co-founder of network medicine, leading cardiovascular researcher, editor-in-chief of Circulation. Co-founder of Scipher Medicine.
**Profile**: https://connects.catalyst.harvard.edu/Profiles/display/Person/412
**Email**: jloscalzo@rics.bwh.harvard.edu

### Vadim N. Gladyshev
**Title**: Professor of Medicine
**Participation Type**: pi
**Role in Project**: Co-Principal Investigator
**Affiliations**: Brigham and Women's Hospital, Harvard Medical School, Gladyshev Lab
**Involvement Period**: {"end":null,"start":"2024-01","status":"ongoing"}
**Responsibilities**:
- Aging biology expertise
- Longevity gene curation
- Supervision
- Writing - review & editing
**Contribution**: Co-Principal Investigator providing aging biology expertise and supervision. No competing interests declared.
**Expertise**: Aging biology, Selenoproteins, Redox biology, Longevity, Epigenetic clocks, Aging biomarkers
**Biography**: Professor of Medicine at Brigham and Women's Hospital, Harvard Medical School. Leading researcher in aging biology, selenoprotein biology, and longevity mechanisms.
**Profile**: https://gladyshevlab.bwh.harvard.edu/
**Email**: vgladyshev@rics.bwh.harvard.edu

### Albert-László Barabási
**Title**: Distinguished Professor
**Participation Type**: pi
**Role in Project**: Principal Investigator, Corresponding Author
**Affiliations**: Network Science Institute, Northeastern University, Barabási Lab
**Involvement Period**: {"end":null,"start":"2024-01","status":"ongoing"}
**Responsibilities**:
- Overall project leadership
- Network medicine methodology development
- Publication lead
- Conceptualization
- Writing - original draft
- Writing - review & editing
**Contribution**: Principal Investigator and corresponding author. Led conceptualization, methodology, and publication. Co-founder of Scipher Medicine (competing interest).
**Expertise**: Network science, Network medicine, Complex systems, Network biology
**Biography**: Distinguished Professor at Network Science Institute, Northeastern University. One of the founders of network medicine, pioneer in network science, author of 'Linked' and 'Bursts'. Corresponding author of the publication. Co-founder of Scipher Medicine.
**Profile**: https://barabasi.com/

## Links

### [Network Topology of Biological Aging and Geroscience-Guided Approaches to COVID-19](https://pubmed.ncbi.nlm.nih.gov/35128530/)
**Type**: research_publication
**Relevance**: secondary
**Category**: related
**Relationship Description**: Network-based analysis of biological aging
**Publisher**: Frontiers in Network Physiology
**Publication Date**: 2022-01-01
**Description**: Network-based analysis of biological aging, demonstrating application of network medicine to aging research

### [Biological mechanisms of aging predict age-related disease co-occurrence in patients](https://pubmed.ncbi.nlm.nih.gov/35259281/)
**Type**: research_publication
**Relevance**: secondary
**Category**: related
**Relationship Description**: Related work on aging mechanisms and disease co-occurrence
**Publisher**: Aging Cell
**Publication Date**: 2022-01-01
**Description**: Related work on aging mechanisms and disease co-occurrence, relevant to network medicine approach
**Metadata**:
```yaml
doi: 10.1111/acel.13524
journal: Aging Cell
```

### [Network Medicine - From Obesity to the 'Diseasome' - NEJM](https://www.nejm.org/doi/full/10.1056/NEJMp0706282)
**Type**: research_publication
**Relevance**: secondary
**Category**: related
**Relationship Description**: Early paper introducing network medicine concepts
**Publisher**: New England Journal of Medicine
**Publication Date**: 2007-01-01
**Description**: Early paper by Barabási introducing network medicine concepts and the 'diseasome'

### [Northeastern University](https://www.northeastern.edu/)
**Type**: website
**Relevance**: secondary
**Category**: reference
**Relationship Description**: Northeastern University website
**Publisher**: Northeastern University
**Description**: Website of Northeastern University

### [Harvard Medical School](https://hms.harvard.edu/)
**Type**: website
**Relevance**: secondary
**Category**: reference
**Relationship Description**: Harvard Medical School website
**Publisher**: Harvard Medical School
**Description**: Website of Harvard Medical School

### [Gladyshev Lab - Brigham and Women's Hospital](https://gladyshevlab.bwh.harvard.edu/)
**Type**: website
**Relevance**: secondary
**Category**: reference
**Relationship Description**: Gladyshev Lab website
**Publisher**: Brigham and Women's Hospital
**Description**: Website of the Gladyshev Lab at Brigham and Women's Hospital

### [Network-driven discovery of repurposable drugs targeting hallmarks of aging - arXiv](https://arxiv.org/abs/2509.03330)
**Type**: research_publication
**Relevance**: primary
**Category**: source
**Relationship Description**: Primary publication on arXiv
**Publisher**: arXiv
**Publication Date**: 2025-09-03
**Description**: Primary publication on arXiv preprint server
**Metadata**:
```yaml
doi: 10.48550/arXiv.2509.03330
arxiv_id: 2509.03330
```

### [Brigham and Women's Hospital](https://www.brighamandwomens.org/)
**Type**: website
**Relevance**: secondary
**Category**: reference
**Relationship Description**: Brigham and Women's Hospital website
**Publisher**: Brigham and Women's Hospital
**Description**: Website of Brigham and Women's Hospital

### [Network Medicine: A Network-based Approach to Human Disease - Nature Reviews Genetics](https://www.nature.com/articles/nrg2918)
**Type**: research_publication
**Relevance**: secondary
**Category**: related
**Relationship Description**: Foundational paper on network medicine by Barabási and Loscalzo
**Publisher**: Nature Reviews Genetics
**Publication Date**: 2011-01-17
**Description**: Foundational paper on network medicine by Barabási, Gulbahce, and Loscalzo
**Metadata**:
```yaml
doi: 10.1038/nrg2918
issue: 1
pages: 56-68
volume: 12
journal: Nature Reviews Genetics
```

### [Joseph Loscalzo - Harvard Catalyst Profile](https://connects.catalyst.harvard.edu/Profiles/display/Person/412)
**Type**: reference
**Relevance**: tertiary
**Category**: reference
**Relationship Description**: Harvard Catalyst profile of Co-PI
**Publisher**: Harvard Catalyst
**Description**: Harvard Catalyst profile of Joseph Loscalzo

### [Loscalzo Lab - Brigham and Women's Hospital](https://www.brighamandwomens.org/research/departments/medicine/cardiovascular-medicine/loscalzo-lab)
**Type**: website
**Relevance**: secondary
**Category**: reference
**Relationship Description**: Loscalzo Lab website
**Publisher**: Brigham and Women's Hospital
**Description**: Website of the Loscalzo Lab at Brigham and Women's Hospital

### [Albert-László Barabási - Wikipedia](https://en.wikipedia.org/wiki/Albert-L%C3%A1szl%C3%B3_Barab%C3%A1si)
**Type**: reference
**Relevance**: tertiary
**Category**: reference
**Relationship Description**: Wikipedia article about Principal Investigator
**Publisher**: Wikipedia
**Description**: Wikipedia article about Albert-László Barabási

### [Albert-László Barabási - Personal Website](https://barabasi.com/)
**Type**: website
**Relevance**: secondary
**Category**: reference
**Relationship Description**: Personal website of Principal Investigator
**Publisher**: Albert-László Barabási
**Description**: Personal website of Albert-László Barabási

### [Network Science Institute, Northeastern University](https://www.networkscienceinstitute.org/)
**Type**: website
**Relevance**: secondary
**Category**: reference
**Relationship Description**: Network Science Institute website
**Publisher**: Network Science Institute
**Description**: Website of the Network Science Institute where Barabási Lab is located

### [Network-driven discovery of repurposable drugs targeting hallmarks of aging - Network Science Institute](https://www.networkscienceinstitute.org/publications/network-driven-discovery-of-repurposable-drugs-targeting-hallmarks-of-aging)
**Type**: research_publication
**Relevance**: primary
**Category**: source
**Relationship Description**: Publication page on Network Science Institute website
**Publisher**: Network Science Institute
**Publication Date**: 2025-09-03
**Description**: Publication page on Network Science Institute website

### [Albert-László Barabási - Google Scholar](https://scholar.google.com/citations?user=vsjWe0wAAAAJ)
**Type**: reference
**Relevance**: tertiary
**Category**: reference
**Relationship Description**: Google Scholar profile of Principal Investigator
**Publisher**: Google Scholar
**Description**: Google Scholar profile of Albert-László Barabási with publications and citations

### [Network Medicine Institute](https://www.network-medicine.org/)
**Type**: website
**Relevance**: secondary
**Category**: related
**Relationship Description**: Network Medicine Institute co-founded by Barabási and Loscalzo
**Publisher**: Network Medicine Institute
**Description**: Global network of 33 universities and institutions advancing network medicine, co-founded by Barabási and Loscalzo

### [Channing Division of Network Medicine - Harvard Medical School](https://www.brighamandwomens.org/research/departments/medicine/channing-division-of-network-medicine)
**Type**: website
**Relevance**: secondary
**Category**: related
**Relationship Description**: Channing Division of Network Medicine co-founded by Barabási and Loscalzo
**Publisher**: Brigham and Women's Hospital
**Description**: Division co-founded by Barabási and Loscalzo, dedicated to network medicine research

### [Non-Coding RNAs Improve the Predictive Power of Network Medicine - arXiv](https://arxiv.org/abs/2211.14800)
**Type**: research_publication
**Relevance**: secondary
**Category**: related
**Relationship Description**: Recent work on enhancing network medicine with non-coding RNAs
**Publisher**: arXiv
**Publication Date**: 2022-11-27
**Description**: Recent work on enhancing network medicine with non-coding RNAs
**Metadata**:
```yaml
arxiv_id: 2211.14800
```

### [Human disease classification in the postgenomic era - Molecular Systems Biology](https://www.embopress.org/doi/10.1038/msb4100163)
**Type**: research_publication
**Relevance**: secondary
**Category**: related
**Relationship Description**: Early work on network-based disease classification
**Publisher**: Molecular Systems Biology
**Publication Date**: 2007-07-10
**Description**: Early work on network-based disease classification
**Metadata**:
```yaml
doi: 10.1038/msb4100163
issue: 1
pages: 124
volume: 3
journal: Molecular Systems Biology
```

### [SHARP Pipeline GitHub Repository](https://github.com/BnayaGross/Longevity-module)
**Type**: github
**Relevance**: primary
**Category**: source
**Relationship Description**: Primary code repository for SHARP pipeline
**Description**: Code and data to reproduce results and figures from the SHARP pipeline study

### [Connectivity Map (CMap)](https://clue.io/)
**Type**: database
**Relevance**: primary
**Category**: source
**Relationship Description**: Drug perturbation expression database used in study for pAGE calculations
**Description**: Drug perturbation expression data source used for pAGE calculations (MCF7 cell line)

### [OpenGenes Database](https://opengenes.org/)
**Type**: database
**Relevance**: primary
**Category**: source
**Relationship Description**: Source database for longevity-associated genes
**Description**: Source of 2,358 longevity-associated genes used in SHARP pipeline

## Financials

### grant
**Source**: European Research Council (ERC)
**Funding Type**: Grant
**Description**: ERC Grant for network science and dynamic systems research
**Details**:
```yaml
note: ERC grant supporting network science and dynamic systems research
grant_id: 810115-DYNASET
```

### grant
**Source**: American Heart Association
**Funding Type**: Grant
**Description**: AHA Grant for cardiovascular and network medicine research
**Details**:
```yaml
note: Grant for cardiovascular and network medicine research
grant_id: D700382
```

### grant
**Source**: American Heart Association
**Funding Type**: Grant
**Description**: AHA Grant for cardiovascular and network medicine research
**Details**:
```yaml
note: Grant for cardiovascular and network medicine research
grant_id: 151708
```

### grant
**Source**: National Institutes of Health (NIH)
**Funding Type**: Grant
**Description**: NIH Grant for cardiovascular and network medicine research
**Details**:
```yaml
note: Grant for cardiovascular and network medicine research
grant_id: HL119145
```

### grant
**Source**: National Institutes of Health (NIH)
**Funding Type**: Grant
**Description**: NIH Grant for cardiovascular and network medicine research
**Details**:
```yaml
note: Grant for cardiovascular and network medicine research
grant_id: HL108630
```

### grant
**Source**: National Institutes of Health (NIH)
**Funding Type**: Grant
**Description**: NIH Grant for genomics and network biology research
**Details**:
```yaml
note: Grant for genomics and network biology research
grant_id: HG007690
```

### grant
**Source**: National Institutes of Health (NIH)
**Funding Type**: Grant
**Description**: NIH Program Project Grant for network medicine and cardiovascular research
**Details**:
```yaml
note: Grant for network medicine and cardiovascular research
grant_id: 1P01HL132825
```

### grant
**Source**: Fulbright Program
**Funding Type**: Fellowship
**Description**: Fulbright Postdoctoral Fellowship
**Details**:
```yaml
type: Postdoctoral Fellowship
recipient: Bnaya Gross
```

### grant
**Source**: European Union Horizon 2021
**Funding Type**: EU Grant
**Description**: EU Horizon 2021 RePO4EU (101057619)
**Details**:
```yaml
program: RePO4EU
grant_id: 101057619
recipient: Joseph Loscalzo
```

### grant
**Source**: European Union Horizon 2020
**Funding Type**: ERC Grant
**Description**: EU Horizon 2020 DYNASNET (810115)
**Details**:
```yaml
program: DYNASNET
grant_id: 810115
recipient: Albert-László Barabási
```

### grant
**Source**: American Heart Association
**Funding Type**: MERIT Award
**Description**: AHA MERIT Award 24MERIT1185447
**Details**:
```yaml
type: MERIT Award
grant_id: 24MERIT1185447
recipient: Joseph Loscalzo
```

### grant
**Source**: American Heart Association
**Funding Type**: Grant
**Description**: AHA Grant 957729
**Details**:
```yaml
grant_id: 957729
recipient: Joseph Loscalzo
```

### grant
**Source**: National Institutes of Health (NIH)
**Funding Type**: U01
**Description**: NIH U01 HG007691
**Details**:
```yaml
grant_id: U01 HG007691
recipient: Joseph Loscalzo
```

### grant
**Source**: National Institutes of Health (NIH)
**Funding Type**: R01
**Description**: NIH R01 HL166137
**Details**:
```yaml
grant_id: R01 HL166137
recipient: Joseph Loscalzo
```

### grant
**Source**: National Institutes of Health (NIH)
**Funding Type**: R01
**Description**: NIH R01 HL155107
**Details**:
```yaml
grant_id: R01 HL155107
recipient: Joseph Loscalzo
```

### grant
**Source**: European Research Council (ERC)
**Funding Type**: ERC Grant
**Description**: ERC Grant 810115-DYNASET
**Details**:
```yaml
note: Network science and dynamic systems
grant_id: 810115-DYNASET
recipient: Albert-László Barabási
```

### grant
**Source**: American Heart Association
**Funding Type**: Grant
**Description**: AHA Grant D700382
**Details**:
```yaml
note: Cardiovascular and network medicine
grant_id: D700382
```

### grant
**Source**: American Heart Association
**Funding Type**: Grant
**Description**: AHA Grant 151708
**Details**:
```yaml
note: Cardiovascular and network medicine
grant_id: 151708
```

### grant
**Source**: National Institutes of Health (NIH)
**Funding Type**: Grant
**Description**: NIH Grant HL119145
**Details**:
```yaml
note: Cardiovascular and network medicine
grant_id: HL119145
```

### grant
**Source**: National Institutes of Health (NIH)
**Funding Type**: Grant
**Description**: NIH Grant HL108630
**Details**:
```yaml
note: Cardiovascular and network medicine
grant_id: HL108630
```

### grant
**Source**: National Institutes of Health (NIH)
**Funding Type**: Grant
**Description**: NIH Grant HG007690
**Details**:
```yaml
note: Genomics and network biology research
grant_id: HG007690
```

### grant
**Source**: National Institutes of Health (NIH)
**Funding Type**: P01
**Description**: NIH Program Project Grant 1P01HL132825
**Details**:
```yaml
note: Network medicine and cardiovascular research
grant_id: 1P01HL132825
```

### grant
**Source**: Fulbright Program
**Funding Type**: Fellowship
**Description**: Fulbright Postdoctoral Fellowship
**Details**:
```yaml
type: Postdoctoral Fellowship
recipient: Bnaya Gross
```

### grant
**Source**: European Union Horizon 2021
**Funding Type**: EU Grant
**Description**: EU Horizon 2021 RePO4EU (101057619)
**Details**:
```yaml
program: RePO4EU
grant_id: 101057619
recipient: Joseph Loscalzo
```

### grant
**Source**: European Union Horizon 2020
**Funding Type**: ERC Grant
**Description**: EU Horizon 2020 DYNASNET (810115)
**Details**:
```yaml
program: DYNASNET
grant_id: 810115
recipient: Albert-László Barabási
```

### grant
**Source**: American Heart Association
**Funding Type**: MERIT Award
**Description**: AHA MERIT Award 24MERIT1185447
**Details**:
```yaml
type: MERIT Award
grant_id: 24MERIT1185447
recipient: Joseph Loscalzo
```

### grant
**Source**: American Heart Association
**Funding Type**: Grant
**Description**: AHA Grant 957729
**Details**:
```yaml
grant_id: 957729
recipient: Joseph Loscalzo
```

### grant
**Source**: National Institutes of Health (NIH)
**Funding Type**: U01
**Description**: NIH U01 HG007691
**Details**:
```yaml
grant_id: U01 HG007691
recipient: Joseph Loscalzo
```

### grant
**Source**: National Institutes of Health (NIH)
**Funding Type**: R01
**Description**: NIH R01 HL166137
**Details**:
```yaml
grant_id: R01 HL166137
recipient: Joseph Loscalzo
```

### grant
**Source**: National Institutes of Health (NIH)
**Funding Type**: R01
**Description**: NIH R01 HL155107
**Details**:
```yaml
grant_id: R01 HL155107
recipient: Joseph Loscalzo
```

### grant
**Source**: European Research Council (ERC)
**Funding Type**: ERC Grant
**Description**: ERC Grant 810115-DYNASET
**Details**:
```yaml
note: Network science and dynamic systems
grant_id: 810115-DYNASET
recipient: Albert-László Barabási
```

### grant
**Source**: American Heart Association
**Funding Type**: Grant
**Description**: AHA Grant D700382
**Details**:
```yaml
note: Cardiovascular and network medicine
grant_id: D700382
```

### grant
**Source**: American Heart Association
**Funding Type**: Grant
**Description**: AHA Grant 151708
**Details**:
```yaml
note: Cardiovascular and network medicine
grant_id: 151708
```

### grant
**Source**: National Institutes of Health (NIH)
**Funding Type**: Grant
**Description**: NIH Grant HL119145
**Details**:
```yaml
note: Cardiovascular and network medicine
grant_id: HL119145
```

### grant
**Source**: National Institutes of Health (NIH)
**Funding Type**: Grant
**Description**: NIH Grant HL108630
**Details**:
```yaml
note: Cardiovascular and network medicine
grant_id: HL108630
```

### grant
**Source**: National Institutes of Health (NIH)
**Funding Type**: Grant
**Description**: NIH Grant HG007690
**Details**:
```yaml
note: Genomics and network biology research
grant_id: HG007690
```

### grant
**Source**: National Institutes of Health (NIH)
**Funding Type**: P01
**Description**: NIH Program Project Grant 1P01HL132825
**Details**:
```yaml
note: Network medicine and cardiovascular research
grant_id: 1P01HL132825
```

### grant
**Source**: Fulbright Program
**Funding Type**: Fellowship
**Description**: Fulbright Postdoctoral Fellowship
**Details**:
```yaml
type: Postdoctoral Fellowship
recipient: Bnaya Gross
```

### grant
**Source**: European Union Horizon 2021
**Funding Type**: EU Grant
**Description**: EU Horizon 2021 RePO4EU (101057619)
**Details**:
```yaml
program: RePO4EU
grant_id: 101057619
recipient: Joseph Loscalzo
```

### grant
**Source**: European Union Horizon 2020
**Funding Type**: ERC Grant
**Description**: EU Horizon 2020 DYNASNET (810115)
**Details**:
```yaml
program: DYNASNET
grant_id: 810115
recipient: Albert-László Barabási
```

### grant
**Source**: American Heart Association
**Funding Type**: MERIT Award
**Description**: AHA MERIT Award 24MERIT1185447
**Details**:
```yaml
type: MERIT Award
grant_id: 24MERIT1185447
recipient: Joseph Loscalzo
```

### grant
**Source**: American Heart Association
**Funding Type**: Grant
**Description**: AHA Grant 957729
**Details**:
```yaml
grant_id: 957729
recipient: Joseph Loscalzo
```

### grant
**Source**: National Institutes of Health (NIH)
**Funding Type**: U01
**Description**: NIH U01 HG007691
**Details**:
```yaml
grant_id: U01 HG007691
recipient: Joseph Loscalzo
```

### grant
**Source**: National Institutes of Health (NIH)
**Funding Type**: R01
**Description**: NIH R01 HL166137
**Details**:
```yaml
grant_id: R01 HL166137
recipient: Joseph Loscalzo
```

### grant
**Source**: National Institutes of Health (NIH)
**Funding Type**: R01
**Description**: NIH R01 HL155107
**Details**:
```yaml
grant_id: R01 HL155107
recipient: Joseph Loscalzo
```

### grant
**Source**: European Research Council (ERC)
**Funding Type**: ERC Grant
**Description**: ERC Grant 810115-DYNASET
**Details**:
```yaml
note: Network science and dynamic systems
grant_id: 810115-DYNASET
recipient: Albert-László Barabási
```

### grant
**Source**: American Heart Association
**Funding Type**: Grant
**Description**: AHA Grant D700382
**Details**:
```yaml
note: Cardiovascular and network medicine
grant_id: D700382
```

### grant
**Source**: American Heart Association
**Funding Type**: Grant
**Description**: AHA Grant 151708
**Details**:
```yaml
note: Cardiovascular and network medicine
grant_id: 151708
```

### grant
**Source**: National Institutes of Health (NIH)
**Funding Type**: Grant
**Description**: NIH Grant HL119145
**Details**:
```yaml
note: Cardiovascular and network medicine
grant_id: HL119145
```

### grant
**Source**: National Institutes of Health (NIH)
**Funding Type**: Grant
**Description**: NIH Grant HL108630
**Details**:
```yaml
note: Cardiovascular and network medicine
grant_id: HL108630
```

### grant
**Source**: National Institutes of Health (NIH)
**Funding Type**: Grant
**Description**: NIH Grant HG007690
**Details**:
```yaml
note: Genomics and network biology research
grant_id: HG007690
```

### grant
**Source**: National Institutes of Health (NIH)
**Funding Type**: P01
**Description**: NIH Program Project Grant 1P01HL132825
**Details**:
```yaml
note: Network medicine and cardiovascular research
grant_id: 1P01HL132825
```

### grant
**Funding Date**: 2024-01-01
**Source**: European Union Horizon 2020
**Funding Type**: ERC Grant
**Description**: DYNASNET Grant (810115)
**Details**:
```yaml
type: ERC
program: DYNASNET
grant_id: 810115
recipient: Albert-László Barabási
```

### grant
**Funding Date**: 2024-01-01
**Source**: National Institutes of Health (NIH)
**Funding Type**: R01
**Description**: R01 HL155107
**Details**:
```yaml
type: R01
grant_id: R01 HL155107
recipient: Joseph Loscalzo
```

### grant
**Funding Date**: 2024-01-01
**Source**: National Institutes of Health (NIH)
**Funding Type**: R01
**Description**: R01 HL166137
**Details**:
```yaml
type: R01
grant_id: R01 HL166137
recipient: Joseph Loscalzo
```

### grant
**Funding Date**: 2024-01-01
**Source**: National Institutes of Health (NIH)
**Funding Type**: U01
**Description**: U01 HG007691
**Details**:
```yaml
type: U01
grant_id: U01 HG007691
recipient: Joseph Loscalzo
```

### grant
**Funding Date**: 2024-01-01
**Source**: American Heart Association
**Funding Type**: Grant
**Description**: AHA Grant 957729
**Details**:
```yaml
grant_id: 957729
recipient: Joseph Loscalzo
```

### grant
**Funding Date**: 2024-01-01
**Source**: American Heart Association
**Funding Type**: MERIT Award
**Description**: AHA24MERIT 1185447
**Details**:
```yaml
type: MERIT Award
grant_id: AHA24MERIT 1185447
recipient: Joseph Loscalzo
```

### grant
**Funding Date**: 2024-01-01
**Source**: European Union Horizon 2021
**Funding Type**: EU Grant
**Description**: RePO4EU Grant (101057619)
**Details**:
```yaml
program: RePO4EU
grant_id: 101057619
recipient: Joseph Loscalzo
```

### grant
**Funding Date**: 2024-01-01
**Source**: Fulbright Program
**Funding Type**: Fellowship
**Description**: Postdoctoral Fellowship
**Details**:
```yaml
type: Postdoctoral Fellowship
recipient: Bnaya Gross
```

## Events

### Publication on arXiv
**Date**: 2025-09-03
**Type**: publication
**Description**: Network-driven discovery of repurposable drugs targeting hallmarks of aging published on arXiv
**Details**:
```yaml
doi: 10.48550/arXiv.2509.03330
url: "https://arxiv.org/abs/2509.03330"
status: arXiv preprint
arxiv_id: 2509.03330
```

### SHARP Pipeline Publication on arXiv
**Date**: 2025-09-03
**Type**: publication
**Description**: Network-driven discovery of repurposable drugs targeting hallmarks of aging published on arXiv
**Details**:
```yaml
doi: 10.48550/arXiv.2509.03330
url: "https://arxiv.org/abs/2509.03330"
status: arXiv preprint
arxiv_id: 2509.03330
key_results:
  drugs_identified: 370
  validation_accuracy_mouse: 90.9%
  validation_accuracy_clinical: 82.4%
```

### SHARP Pipeline Publication on arXiv
**Date**: 2025-09-03
**Type**: publication
**Description**: Network-driven discovery of repurposable drugs targeting hallmarks of aging published on arXiv
**Details**:
```yaml
doi: 10.48550/arXiv.2509.03330
url: "https://arxiv.org/abs/2509.03330"
status: arXiv preprint
arxiv_id: 2509.03330
key_results:
  drugs_identified: 370
  validation_accuracy_mouse: 90.9%
  validation_accuracy_clinical: 82.4%
```

### SHARP Pipeline Publication on arXiv
**Date**: 2025-09-03
**Type**: publication
**Description**: Network-driven discovery of repurposable drugs targeting hallmarks of aging published on arXiv
**Details**:
```yaml
doi: 10.48550/arXiv.2509.03330
url: "https://arxiv.org/abs/2509.03330"
status: arXiv preprint
arxiv_id: 2509.03330
key_results:
  drugs_identified: 370
  validation_accuracy_mouse: 90.9%
  validation_accuracy_clinical: 82.4%
```

## Partnerships

### research
**Focus**: Network medicine approach for drug repurposing targeting hallmarks of aging
**Description**: Multi-institutional research collaboration between Network Science Institute (Northeastern University), Brigham and Women's Hospital, and Harvard Medical School
**Partner Organizations**:
- Harvard Medical School (partner)
  - Academic partner providing affiliation for Gladyshev Lab and Loscalzo Lab
- Brigham and Women's Hospital (partner)
  - Research collaboration partner hosting Gladyshev Lab and Loscalzo Lab
- Network Science Institute, Northeastern University (partner)
  - Primary development institution hosting Barabási Lab
**Details**:
```yaml
governance: Co-led by Principal Investigators Albert-László Barabási (corresponding author), Vadim N. Gladyshev, and Joseph Loscalzo
participants:
  - Barabási Lab (Network Science Institute, Northeastern University)
  - "Gladyshev Lab (Brigham and Women's Hospital, Harvard Medical School)"
  - "Loscalzo Lab (Brigham and Women's Hospital, Harvard Medical School)"
collaboration_period:
  start: 2024
  publication_date: 2025-09-03
```

### research
**Focus**: Network medicine approach for drug repurposing targeting hallmarks of aging
**Description**: Multi-institutional research collaboration for SHARP pipeline development
**Partner Organizations**:
- Harvard Medical School (partner)
  - Academic partner providing affiliation
- Brigham and Women's Hospital (partner)
  - Research collaboration partner hosting Gladyshev Lab and Loscalzo Lab
- Network Science Institute, Northeastern University (partner)
  - Primary development institution hosting Barabási Lab
**Details**:
```yaml
output: "SHARP: Systematic Hallmark-based Aging Repurposing Pipeline"
governance: Co-led by Albert-László Barabási (corresponding author), Vadim N. Gladyshev, and Joseph Loscalzo
participants:
  - Barabási Lab (Network Science Institute, Northeastern University)
  - "Gladyshev Lab (Brigham and Women's Hospital, Harvard Medical School)"
  - "Loscalzo Lab (Brigham and Women's Hospital, Harvard Medical School)"
collaboration_period:
  start: 2024
  publication_date: 2025-09-03
```

### research
**Focus**: Network medicine approach for drug repurposing targeting hallmarks of aging
**Description**: Multi-institutional research collaboration for SHARP pipeline development
**Partner Organizations**:
- Harvard Medical School (partner)
  - Academic partner providing affiliation
- Brigham and Women's Hospital (partner)
  - Research collaboration partner hosting Gladyshev Lab and Loscalzo Lab
- Network Science Institute, Northeastern University (partner)
  - Primary development institution hosting Barabási Lab
**Details**:
```yaml
output: "SHARP: Systematic Hallmark-based Aging Repurposing Pipeline"
governance: Co-led by Albert-László Barabási (corresponding author), Vadim N. Gladyshev, and Joseph Loscalzo
participants:
  - Barabási Lab (Network Science Institute, Northeastern University)
  - "Gladyshev Lab (Brigham and Women's Hospital, Harvard Medical School)"
  - "Loscalzo Lab (Brigham and Women's Hospital, Harvard Medical School)"
collaboration_period:
  start: 2024
  publication_date: 2025-09-03
```

### research
**Focus**: Network medicine approach for drug repurposing targeting hallmarks of aging
**Description**: Multi-institutional research collaboration for SHARP pipeline development
**Partner Organizations**:
- Harvard Medical School (partner)
  - Academic partner providing affiliation
- Brigham and Women's Hospital (partner)
  - Research collaboration partner hosting Gladyshev Lab and Loscalzo Lab
- Network Science Institute, Northeastern University (partner)
  - Primary development institution hosting Barabási Lab
**Details**:
```yaml
output: "SHARP: Systematic Hallmark-based Aging Repurposing Pipeline"
governance: Co-led by Albert-László Barabási (corresponding author), Vadim N. Gladyshev, and Joseph Loscalzo
participants:
  - Barabási Lab (Network Science Institute, Northeastern University)
  - "Gladyshev Lab (Brigham and Women's Hospital, Harvard Medical School)"
  - "Loscalzo Lab (Brigham and Women's Hospital, Harvard Medical School)"
collaboration_period:
  start: 2024
  publication_date: 2025-09-03
```
